Patients with kidney disease often avoid common pain relievers like aspirin, ibuprofen and naproxen. These medications have the potential to exacerbate existing conditions and create life-threatening drug interactions. As an alternative to drug-based relief for kidney-compromised patients, Maryland Medicaid will now offer reimbursement for BioElectronics’ ActiPatch.
ActiPatch is a drug-free anti-inflammatory patch which accelerates healing while reducing soft tissue pain and swelling through the use of pulsed electromagnetic frequency (PEMF) therapy. The thin patch uses an embedded battery to deliver continuous pulsed RF therapy to an injury site.
Watch this video (featuring what appears to be an animatronic host) to learn more.
ActiPatch was cleared by the FDA for the treatment of edema following blepharoplasty, a procedure in which the physician surgically removes excess fat, muscle, and skin from both the upper and lower eyelids. The device is also approved in Canada and Europe for the relief of pain in musculoskeletal conditions.
In 2006, the company and the Lahey Clinic announced a three-year program to study the effects of ActiPatch Therapy on a variety of soft tissue injuries. Results from these clinical trials will be submitted to the FDA for expanded indications for the use of ActiPatch.
The company is actively pursuing additional reimbursement approvals nationally.
BioElectronics Corp. opened at $.036 today. The stock, which trades on the pink sheets, has experienced a steady decline since 2006, surprising considering the ramp up in domestic and international sales and marketing activity.
